Showing results (71-80 of 302) with videos related to

Sort By:
Pageof 31
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphomaEhsan Irajizad, Johannes F Fahrmann, Hiroyuki Katayama, et al.
Advances in Radiation Oncology|November 11, 2024
Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the LungSusan Y Wu, Penny Q Fang, Ahmed Fetooh, et al.
Blood Advances|June 27, 2020
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaChelsea C Pinnix, Jillian R Gunther, Bouthaina S Dabaja, et al.
Lab on a Chip|January 6, 2017
3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitroRobert G Mannino, Adriana N Santiago-Miranda, Pallab Pradhan, et al.
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
Blood Advances|December 24, 2019
Venetoclax for AML: changing the treatment paradigmDaniel A Pollyea, Maria Amaya, Paolo Strati, et al.
The Lancet. Haematology|January 18, 2021
Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?Carlota Gudiol, Russell E Lewis, Paolo Strati, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2012
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibodyPaolo Strati, Jorge Cortes, Stefan Faderl, et al.
Blood Advances|February 5, 2025
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomasDai Chihara, Raphael E Steiner, Ranjit Nair, et al.
Haematologica|November 30, 2023
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapyAndrew P Jallouk, Naishu Kui, Ryan Sun, et al.
Pageof 31